Literature DB >> 22189939

Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds.

Christian R Kowol1, Petra Heffeter, Walter Miklos, Lars Gille, Robert Trondl, Loredana Cappellacci, Walter Berger, Bernhard K Keppler.   

Abstract

Intracellular generation of reactive oxygen species (n class="Chemical">ROS) via thiol-mediated reduction of copper(II) to copper(I) has been assumed as the major mechanism underlying the anticancer activity of copper(II) complexes. The aim of this study was to compare the anticancer potential of copper(II) complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; currently in phase II clinical trials) and its terminally dimethylated derivative with that of 2-formylpyridine thiosemicarbazone and that of 2,2'-bipyridyl-6-carbothioamide. Experiments on generation of oxidative stress and the influence of biologically relevant reductants (glutathione, ascorbic acid) on the anticancer activity of the copper complexes revealed that reductant-dependent redox cycling occurred mainly outside the cells, leading to generation and dismutation of superoxide radicals resulting in cytotoxic amounts of H(2)O(2). However, without extracellular reductants only weak intracellular ROS generation was observed at IC(50) levels, suggesting that cellular thiols are not involved in copper-complex-induced oxidative stress. Taken together, thiol-induced intracellular ROS generation might contribute to the anticancer activity of copper thiosemicarbazone complexes but is not the determining factor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189939      PMCID: PMC3371635          DOI: 10.1007/s00775-011-0864-x

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  43 in total

1.  Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity.

Authors:  Patric J Jansson; Philip C Sharpe; Paul V Bernhardt; Des R Richardson
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

2.  Synthesis and reactivity studies on new copper(II) complexes: DNA binding, generation of phenoxyl radical, SOD and nuclease activities.

Authors:  Kaushik Ghosh; Pramod Kumar; Nidhi Tyagi; Udai P Singh; Vaibhave Aggarwal; Maria Camilla Baratto
Journal:  Eur J Med Chem       Date:  2010-05-19       Impact factor: 6.514

3.  Interaction of 2-formylpyridine thiosemicarbazonato copper (II) with Ehrlich ascites tumor cells.

Authors:  L A Saryan; K Mailer; C Krishnamurti; W Antholine; D H Petering
Journal:  Biochem Pharmacol       Date:  1981-06-15       Impact factor: 5.858

4.  Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox.

Authors:  M Grusch; M Fritzer-Szekeres; G Fuhrmann; G Rosenberger; C Luxbacher; H L Elford; K Smid; G J Peters; T Szekeres; G Krupitza
Journal:  Exp Hematol       Date:  2001-05       Impact factor: 3.084

Review 5.  Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.

Authors:  William A Denny
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

Review 6.  From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

Authors:  Christian G Hartinger; Stefanie Zorbas-Seifried; Michael A Jakupec; Bernd Kynast; Haralabos Zorbas; Bernhard K Keppler
Journal:  J Inorg Biochem       Date:  2006-02-28       Impact factor: 4.155

7.  In vitro and in vivo evaluation of bifunctional bisthiosemicarbazone 64Cu-complexes for the positron emission tomography imaging of hypoxia.

Authors:  Paul D Bonnitcha; Amy L Vāvere; Jason S Lewis; Jonathan R Dilworth
Journal:  J Med Chem       Date:  2008-04-17       Impact factor: 7.446

8.  A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.

Authors:  Judith E Karp; Francis J Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; Bonny Johnson; Mya Thein; Mario Sznol; Jennifer Low
Journal:  Leuk Res       Date:  2007-07-20       Impact factor: 3.156

Review 9.  Anticancer activity of metal complexes: involvement of redox processes.

Authors:  Ute Jungwirth; Christian R Kowol; Bernhard K Keppler; Christian G Hartinger; Walter Berger; Petra Heffeter
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

10.  Insights into the mode of action of the anti-Candida activity of 1,10-phenanthroline and its metal chelates.

Authors:  M McCann; M Geraghty; M Devereux; D O'Shea; J Mason; L O'Sullivan
Journal:  Met Based Drugs       Date:  2000
View more
  20 in total

1.  Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.

Authors:  Kimiko Ishiguro; Z Ping Lin; Philip G Penketh; Krishnamurthy Shyam; Rui Zhu; Raymond P Baumann; Yong-Lian Zhu; Alan C Sartorelli; Thomas J Rutherford; Elena S Ratner
Journal:  Biochem Pharmacol       Date:  2014-08-15       Impact factor: 5.858

2.  High cytotoxicity of vanadium(IV) complexes with 1,10-phenanthroline and related ligands is due to decomposition in cell culture medium.

Authors:  Maria Le; Oliver Rathje; Aviva Levina; Peter A Lay
Journal:  J Biol Inorg Chem       Date:  2017-04-03       Impact factor: 3.358

3.  Enhanced cellular uptake and photochemotherapeutic potential of a lipophilic strained Ru(ii) polypyridyl complex.

Authors:  Stephanie Mehanna; Najwa Mansour; Hassib Audi; Kikki Bodman-Smith; Mohamad A Mroueh; Robin I Taleb; Costantine F Daher; Rony S Khnayzer
Journal:  RSC Adv       Date:  2019-06-03       Impact factor: 4.036

4.  Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities.

Authors:  R Dornetshuber-Fleiss; P Heffeter; T Mohr; P Hazemi; K Kryeziu; C Seger; W Berger; R Lemmens-Gruber
Journal:  Biochem Pharmacol       Date:  2013-06-06       Impact factor: 5.858

5.  Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing CN-Chelated and Pyridine Ligands.

Authors:  Zhe Liu; Isolda Romero-Canelón; Abraha Habtemariam; Guy J Clarkson; Peter J Sadler
Journal:  Organometallics       Date:  2014-09-09       Impact factor: 3.876

6.  Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity.

Authors:  Henning Karlsson; Mårten Fryknäs; Sara Strese; Joachim Gullbo; Gunnar Westman; Ulf Bremberg; Tobias Sjöblom; Tatjana Pandzic; Rolf Larsson; Peter Nygren
Journal:  Oncotarget       Date:  2017-05-02

7.  β-Carboline copper complex as a potential mitochondrial-targeted anticancer chemotherapeutic agent: Favorable attenuation of human breast cancer MCF7 cells via apoptosis.

Authors:  Rais Ahmad Khan; Mohammad Rashid Khan; Mohammad Usman; Fatima Sayeed; Huda A Alghamdi; Sulaiman Alrumman; Walaa Alharbi; Nida N Farshori; Mai M Al-Oqail; Mohd Rafiq Siddiqui; Maymonah Abu Khanjer; Ali Alsalme
Journal:  Saudi J Biol Sci       Date:  2020-05-08       Impact factor: 4.219

8.  Copper(II) Thiosemicarbazone Complexes and Their Proligands upon UVA Irradiation: An EPR and Spectrophotometric Steady-State Study.

Authors:  Michal Hricovíni; Milan Mazúr; Angela Sîrbu; Oleg Palamarciuc; Vladimir B Arion; Vlasta Brezová
Journal:  Molecules       Date:  2018-03-21       Impact factor: 4.411

9.  Binding Models of Copper(II) Thiosemicarbazone Complexes with Human Serum Albumin: A Speciation Study.

Authors:  Nóra V May; Attila Jancsó; Éva A Enyedy
Journal:  Molecules       Date:  2021-05-05       Impact factor: 4.411

10.  Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis.

Authors:  Daniela Lötsch; Elisabeth Steiner; Klaus Holzmann; Sabine Spiegl-Kreinecker; Christine Pirker; Juraj Hlavaty; Helga Petznek; Balazs Hegedus; Tamas Garay; Thomas Mohr; Wolfgang Sommergruber; Michael Grusch; Walter Berger
Journal:  Oncotarget       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.